Progenity and Ionis Pharmaceuticals Enter into Agreement to Evaluate Progenity’s Ingestible Oral Biotherapeutics Technology for Delivery of Antisense Therapies Nasdaq:PROG

Progenity and Ionis Pharmaceuticals Enter into Agreement to Evaluate Progenity’s Ingestible Oral Biotherapeutics Technology for Delivery of Antisense Therapies Nasdaq:PROG

News Highlights

SAN DIEGO, April 06, 2021 (News) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced an agreement with Ionis Pharmaceuticals, the leader in RNA-targeted therapeutics, to evaluate the safety, tolerability and performance of Progenity’s Oral Biotherapeutics Delivery System (OBDS) for oral systemic delivery of antisense oligonucleotides, developed and manufactured by Ionis.

Ionis’ novel antisense therapies are designed to target mRNA in a highly specific manner, so that the amount of disease-causing protein is dramatically decreased. Antisense therapies can also treat diseases caused by too little protein by increasing the production of the protein, thereby restoring the protein to normal levels.

The OBDS is an ingestible capsule based on a needle-free technology designed by Progenity to enable delivery of a drug formulated in a solution directly into the tissues of the small intestine, where it can be absorbed systemically.

“We’re excited to work with Ionis, a leader in nucleic-acid-based biotherapeutics, to collectively evaluate the ODBS platform for the oral delivery of antisense therapies,” said Harry Stylli, PhD, CEO, chairman of the board and co-founder of Progenity. “We believe the OBDS platform shows promise to transform the systemic delivery of diverse biotherapeutics via oral administration. Our primary focus has been the oral delivery of monoclonals, proteins, and peptides, and now we are potentially able to expand into nucleic-acid-based therapeutics.”

During the first phase of the study, Progenity and Ionis will evaluate the OBDS in conjunction with Ionis’ drug for in vitro compatibility and performance as well as in vivo safety, tolerability and performance in a preclinical canine model.

Progenity is developing an internal pipeline including PGN-OB1, an oral version of adalimumab and PGN-OB2, an oral version of a GLP-1 analog. The company expects that this collaboration could further demonstrate the versatility of the OBDS in delivering a range of different molecules.

ABOUT PROGENITY, INC. Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company’s website at www.progenity.com.

FORWARD LOOKING STATEMENTS This press release contains “forward-looking statements,” which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements regarding the development progress of our Oral Biotherapeutics Delivery System (OBDS), its future use with antisense therapies, and the performance of OBDS in an upcoming preclinical study. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause the Company’s actual results to differ materially from the forward-looking statements expressed or implied in this press release, including the ongoing COVID-19 pandemic and associated shelter-in-place orders, our ability to develop and commercialize our testing products, the performance of third parties in connection with the commercialization and development of our products, regulatory developments in the United States and foreign countries, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our ability to improve and enhance our products, our plans to research, develop, and commercialize new products, the development, regulatory approval, efficacy, and commercialization of competing products, the loss or retirement of key scientific or management personnel, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 18, 2021, and other subsequent documents we file with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:Robert UhlManaging Director, Westwicke ICRir@progenity.com (619) 228-5886

Progenity Media Contact:Kate Blom-LoweryCG Lifemedia@progenity.com(619) 743-6294

  • Check the latest Health news updates and information.
  • Please share this news Progenity and Ionis Pharmaceuticals Enter into Agreement to Evaluate Progenity’s Ingestible Oral Biotherapeutics Technology for Delivery of Antisense Therapies Nasdaq:PROG with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Netatmo HomeKit Secure Video support for Smart Outdoor Cameras

Netatmo HomeKit Secure Video support for Smart Outdoor Cameras

As promised, existing Outdoor Cameras will get the update within the next few days Netatmo HomeKit Secure Video (HSV) support is now arriving for the ...
Despite the scams, Australian securities regulator wants to support the crypto industry

Despite the scams, Australian securities regulator wants to support the crypto industry

“We know that this is probably a concern as much to all of you who participate in the industry as it is to us.” “As part of our job in dealing with consumer ...
Oprah Winfrey turns down talks of police raid and arrest

Oprah Winfrey turns down talks of police raid and arrest

The 66-year-old talk show host and media mogul became one of Twitter’s top trending topics on Tuesday night after rumors began circulating on social media ...
XGS Series Firewall Appliances- Industry-Best Transport Layer Security (TLS) Inspection unveiled by Sophos 

XGS Series Firewall Appliances- Industry-Best Transport Layer Security (TLS) Inspection unveiled by Sophos 

Cybercriminals Increasingly Using TLS to Avoid Detection Sophos today also published new research, “Nearly Half of Malware Now Use TLS to Conceal ...
Blast Auxiliary AC Reviews -Is Blast Auxiliary personal air cooler legit or scam?

Blast Auxiliary AC Reviews -Is Blast Auxiliary personal air cooler legit or scam?

Despite being such a popular product, it is still new for many people, especially those who are not much active online. As we are almost entering the summer, ...
Ezekiel Emanuel wants great reflection for new government health IT projects

Ezekiel Emanuel wants great reflection for new government health IT projects

Emanuel noted – correctly, as recent news has shown – that such cards can be easily fabricated.   Emanuel pointed to the reliance on analog tools amidst the ...
Mother of Cumberland Co. accused of lying about her daughter’s health, collecting donations

Mother of Cumberland Co. accused of lying about her daughter’s health, collecting donations

Police say Noreika also created digital fundraising campaigns to cover medical costs and reached out to local organizations and churches, collecting a total of ...
North Texas doctor shares how you can protect your mental and emotional health amid a difficult year of mass shootings and police violence

North Texas doctor shares how you can protect your mental and emotional health amid a difficult year of mass shootings and police violence

”You have to do some intentional deliberate things to keep the balance in life,” advised Lankford.  She said the graphic images on constant replay can be ...
Xiaomi New Mi Mix Rumors Same Frame with Samsung Galaxy Z Fold 2; what all you need to know

Xiaomi New Mi Mix Rumors Same Frame with Samsung Galaxy Z Fold 2; what all you need to know

  Xiaomi already confirms that it will unveil the new Mi 11 Pro and M11 ultra and some other devices on its upcoming hardware event, which is expected to ...
Show next
Compsmag - Latest News from tech, business and health
Logo